{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T01:50:58Z","timestamp":1694829058010},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1007\/s00120-005-0958-6","type":"journal-article","created":{"date-parts":[[2005,11,21]],"date-time":"2005-11-21T16:14:33Z","timestamp":1132589673000},"page":"9-17","source":"Crossref","is-referenced-by-count":5,"title":["Moderne Immunsuppressiva nach Nierentransplantation"],"prefix":"10.1007","volume":"45","author":[{"given":"K.","family":"Budde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Giessing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Liefeldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.-H.","family":"Neumayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Glander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"958_CR1","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM199912023412303","volume":"341","author":"Wolfe","year":"1999","unstructured":"Wolfe RA, Ashby VB, Milford EL et al. (1999) Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341: 1725\u20131730","journal-title":"N Engl J Med"},{"key":"958_CR2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2648.2005.03455.x","volume":"51","author":"Shu-Fen","year":"2005","unstructured":"Shu-Fen N, Chuan LI (2005) Quality of life of patients having renal replacement therapy. J Adv Nurs 51: 15\u201321","journal-title":"J Adv Nurs"},{"key":"958_CR3","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/bmj.324.7336.530","volume":"324","author":"Andrews","year":"2002","unstructured":"Andrews PA (2002) Renal transplantation. BMJ 324: 530\u2013534","journal-title":"BMJ"},{"key":"958_CR4","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/S0041-1345(98)00213-9","volume":"30","author":"Vanrenterghem","year":"1998","unstructured":"Vanrenterghem Y (1998) Role of acute rejection in chronic rejection. Transplant Proc 30: 1210\u20131211","journal-title":"Transplant Proc"},{"key":"958_CR5","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1056\/NEJMra033540","volume":"351","author":"Halloran","year":"2004","unstructured":"Halloran PF (2004) Immunosuppressive drugs for kidney transplantation. N Engl J Med 351: 2715\u20132729","journal-title":"N Engl J Med"},{"key":"958_CR6","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1600-6143.2004.00332.x","volume":"4","author":"Meier-Kriesche","year":"2004","unstructured":"Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B (2004) Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4: 378\u2013383","journal-title":"Am J Transplant"},{"key":"958_CR7","first-page":"391","volume":"1992","author":"Koyama","year":"1992","unstructured":"Koyama H, Cecka JM (1992) Rejection episodes. Clin Transpl 1992: 391\u2013404","journal-title":"Clin Transpl"},{"key":"958_CR8","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/00007890-199604150-00008","volume":"61","author":"The","year":"1996","unstructured":"The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group (1996) A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61: 1029\u20131037","journal-title":"Transplantation"},{"key":"958_CR9","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/01.TP.0000155430.52845.51","volume":"79","author":"Flechner","year":"2005","unstructured":"Flechner SM, Feng J, Mastroianni B et al. (2005) The effect of 2-gram versus 1-gram concentration controlled mycophenolate mofetil on renal transplant outcomes using sirolimus-based calcineurin inhibitor drug-free immunosuppression. Transplantation 79: 926\u2013934","journal-title":"Transplantation"},{"key":"958_CR10","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMra011295","volume":"346","author":"Pascual","year":"2002","unstructured":"Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB (2002) Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 346: 580\u2013590","journal-title":"N Engl J Med"},{"key":"958_CR11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00007691-199111000-00001","volume":"13","author":"Lindholm","year":"1991","unstructured":"Lindholm A (1991) Factors influencing the pharmacokinetics of cyclosporine in man. Ther Drug Monit 13: 465\u2013477","journal-title":"Ther Drug Monit"},{"key":"958_CR12","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/00002018-200225100-00003","volume":"25","author":"van Gelder","year":"2002","unstructured":"van Gelder T (2002) Drug interactions with tacrolimus. Drug Saf 25: 707\u2013712","journal-title":"Drug Saf"},{"key":"958_CR13","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/00007890-200203270-00003","volume":"73","author":"Holt","year":"2002","unstructured":"Holt DW (2002) Cyclosporin monitoring based on C2 sampling. Transplantation 73: 840\u2013841","journal-title":"Transplantation"},{"key":"958_CR14","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1034\/j.1399-0012.2002.02036.x","volume":"16","author":"Pescovitz","year":"2002","unstructured":"Pescovitz MD, Barbeito R, Simulect US01 Study Group (2002) Two-hour post-dose cyclosporine level is a better predictor than trough level of acute rejection of renal allografts. Clin Transplant 16: 378\u2013382","journal-title":"Clin Transplant"},{"key":"958_CR15","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1749-6632.1993.tb35897.x","volume":"685","author":"Elion","year":"1993","unstructured":"Elion GB (1993) The George Hitchings and Gertrude Elion Lecture. The pharmacology of azathioprine. Ann NY Acad Sci 685: 400\u2013407","journal-title":"Ann NY Acad Sci"},{"key":"958_CR16","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1172\/JCI16432","volume":"111","author":"Tiede","year":"2003","unstructured":"Tiede I, Fritz G, Strand S et al. (2003) CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 111: 1133\u20131145","journal-title":"J Clin Invest"},{"key":"958_CR17","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/00007890-199702150-00010","volume":"63","author":"Kunz","year":"1997","unstructured":"Kunz R, Neumayer HH (1997) Maintenance therapy with triple versus double immunosuppressive regimen in renal transplantation: a meta-analysis. Transplantation 63: 386\u2013392","journal-title":"Transplantation"},{"key":"958_CR18","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(95)92534-1","volume":"345","author":"European","year":"1995","unstructured":"European Mycophenolate Mofetil Cooperative Study Group (1995) Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345: 1321\u20131325","journal-title":"Lancet"},{"key":"958_CR19","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/00007890-199604150-00008","volume":"61","author":"The","year":"1996","unstructured":"The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group (1996) A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61: 1029\u20131037","journal-title":"Transplantation"},{"key":"958_CR20","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1517\/14656566.5.6.1333","volume":"5","author":"Budde","year":"2004","unstructured":"Budde K, Glander P, Diekmann F et al. (2004) Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother 5: 1333\u20131345","journal-title":"Expert Opin Pharmacother"},{"key":"958_CR21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00007890-199508000-00003","volume":"60","author":"Sollinger","year":"1995","unstructured":"Sollinger HW for the US Renal Transplant Mycophenolate Mofetil Study Group (1995) Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60: 225\u2013232","journal-title":"Transplantation"},{"key":"958_CR22","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1097\/00007890-200006150-00033","volume":"69","author":"Ojo","year":"2000","unstructured":"Ojo AO, Meier-Kriesche HU, Hanson JA et al. (2000) Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 69: 2405\u20132409","journal-title":"Transplantation"},{"key":"958_CR23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0041-1345(03)00211-2","volume":"35","author":"Sehgal","year":"2003","unstructured":"Sehgal SN (2003) Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 35 [Suppl 3]: 7\u201314","journal-title":"Transplant Proc"},{"key":"958_CR24","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/00007890-199810270-00013","volume":"66","author":"Kahan","year":"1998","unstructured":"Kahan, Barry D, Podbielski J et al. (1998) Immunosuppressive effects and safety of a sirolimus\/cyclosporine combination regimen for renal transplantation. Transplantation 66: 1040\u20131046","journal-title":"Transplantation"},{"key":"958_CR25","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1111\/j.1600-6143.2004.00590.x","volume":"4","author":"Diekmann","year":"2004","unstructured":"Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM (2004) Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 4: 1869\u20131875","journal-title":"Am J Transplant"},{"key":"958_CR26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1046\/j.1600-6135.2003.00279.x","volume":"4","author":"Fritsche","year":"2004","unstructured":"Fritsche L, Budde K, Dragun D, Einecke G, Diekmann F, Neumayer HH (2004) Testosterone concentrations and sirolimus in male renal transplant patients. Am J Transplant 4: 130\u2013131","journal-title":"Am J Transplant"},{"key":"958_CR27","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1517\/13543784.11.12.1845","volume":"11","author":"Nashan","year":"2002","unstructured":"Nashan B (2002) Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs 11: 1845\u20131157","journal-title":"Expert Opin Investig Drugs"},{"key":"958_CR28","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0041-1345(98)01919-8","volume":"31","author":"Abramowicz","year":"1999","unstructured":"Abramowicz D, Wissing M (1999) S206 Induction protocols: yesterday, today, and tomorrow. Transplant Proc 31: 1100\u20131101","journal-title":"Transplant Proc"},{"key":"958_CR29","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/S0140-6736(05)80084-4","volume":"342","author":"Opelz","year":"1993","unstructured":"Opelz G, Henderson R (1993) Incidence of Non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 342: 1514\u20131516","journal-title":"Lancet"},{"key":"958_CR30","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM199801153380304","volume":"338","author":"Vincenti","year":"1998","unstructured":"Vincenti F, Kirkman R, Light S et al. (1998) Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 338: 161\u2013165","journal-title":"N Engl J Med"},{"key":"958_CR31","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S0140-6736(97)09278-7","volume":"350","author":"Nashan","year":"1997","unstructured":"Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP (1997) Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 350: 1193\u20131188","journal-title":"Lancet"},{"key":"958_CR32","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1517\/14656566.6.5.787","volume":"6","author":"Kaltwasser","year":"2005","unstructured":"Kaltwasser JP, Behrens F (2005) Leflunomide: long-term clinical experience and new uses. Expert Opin Pharmacother 6: 787\u2013801","journal-title":"Expert Opin Pharmacother"},{"key":"958_CR33","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1034\/j.1600-6143.2002.20909.x","volume":"2","author":"Hardinger","year":"2002","unstructured":"Hardinger KL, Wang CD, Schnitzler MA et al. (2002) Prospective, pilot, open-label, short-term study of conversion to leflunomide reverses chronic renal allograft dysfunction. Am J Transplant 2: 867\u2013871","journal-title":"Am J Transplant"},{"key":"958_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2004.03.007","volume":"65","author":"Evers","year":"2005","unstructured":"Evers DL, Wang X, Huong SM, Andreoni KA, Huang ES (2005) Inhibition of human cytomegalovirus signaling and replication by the immunosuppressant FK778. Antiviral Res 65: 1\u201312","journal-title":"Antiviral Res"},{"key":"958_CR35","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3349\/ymj.2004.45.6.1132","volume":"45","author":"Fitzsimmons","year":"2004","unstructured":"Fitzsimmons WE, First MR (2004) FK778, a synthetic malononitrilamide. Yonsei Med J 45: 1132\u20131135","journal-title":"Yonsei Med J"},{"key":"958_CR36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/01.TP.0000132562.54089.62","volume":"78","author":"Vanrenterghem","year":"2004","unstructured":"Vanrenterghem Y, van Hooff JP, Klinger M et al. (2004) The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients. Transplantation 78: 9\u201314","journal-title":"Transplantation"},{"key":"958_CR37","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1600-6143.2004.00476.x","volume":"4","author":"Brinkmann","year":"2004","unstructured":"Brinkmann V, Cyster JG, Hla T (2004) FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 4: 1019\u20131025","journal-title":"Am J Transplant"},{"key":"958_CR38","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1681\/ASN.V1341073","volume":"13","author":"Budde","year":"2002","unstructured":"Budde K, Schmouder RL, Brunkhorst R et al. (2002) First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 13: 1073\u20131083","journal-title":"J Am Soc Nephrol"},{"key":"958_CR39","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/01.TP.0000071362.99021.D9","volume":"76","author":"Kirk","year":"2003","unstructured":"Kirk AD, Hale DA, Mannon RB et al. (2003) Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 76: 120\u2013129","journal-title":"Transplantation"},{"key":"958_CR40","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/j.1600-6143.2004.00454.x","volume":"4","author":"Becker","year":"2004","unstructured":"Becker YT, Becker BN, Pirsch JD, Sollinger HW (2004) Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 4: 996\u20131001","journal-title":"Am J Transplant"},{"key":"958_CR41","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1600-6143.2005.00749.x","volume":"5","author":"Larsen","year":"2005","unstructured":"Larsen CP, Pearson TC, Adams AB et al. (2005) Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 5: 443\u2013453","journal-title":"Am J Transplant"},{"key":"958_CR42","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/01.TP.0000165109.06382.56","volume":"80","author":"Rama","year":"2005","unstructured":"Rama I, Cruzado JM, Gil-Vernet S et al. (2005) Steroids can be safely withdrawn from cyclosporine and mycophenolate mofetil-treated renal allograft recipients: long-term results. Transplantation 80: 164\u2013168","journal-title":"Transplantation"},{"key":"958_CR43","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1097\/01.TP.0000062833.14843.4B","volume":"75","author":"Meier-Kriesche","year":"2003","unstructured":"Meier-Kriesche HU, Steffen BJ, Hochberg AM et al. (2003) Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 75: 1341\u20131346","journal-title":"Transplantation"},{"key":"958_CR44","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1517\/13543784.11.12.1845","volume":"11","author":"Nashan","year":"2002","unstructured":"Nashan B (2002) Review of the proliferation inhibitor everolimus. Expert Opin Invest Drugs 11: 1845\u20131857","journal-title":"Expert Opin Invest Drugs"},{"key":"958_CR45","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1432-2277.2004.00052.x","volume":"18","author":"Oberbauer","year":"2005","unstructured":"Oberbauer R, Segoloni G, Campistol JM et al. (2005) Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 18: 22\u201328","journal-title":"Transpl Int"},{"key":"958_CR46","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1111\/j.1600-6143.2004.00617.x","volume":"4","author":"Glander","year":"2004","unstructured":"Glander P, Hambach P, Braun KP et al. (2004) Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant 4: 2045\u20132051","journal-title":"Am J Transplant"},{"key":"958_CR47","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/00007890-199804150-00013","volume":"65","author":"Fischereder","year":"1998","unstructured":"Fischereder M, Gohring P, Schneeberger H et al. (1998) Early loss of renal transplants in patients with thrombophilia. Transplantation 65: 936\u2013939","journal-title":"Transplantation"},{"key":"958_CR48","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/01.ASN.0000039567.22063.9D","volume":"14","author":"Heidenreich","year":"2003","unstructured":"Heidenreich S, Junker R, Wolters H et al. (2003) Outcome of kidney transplantation in patients with inherited thrombophilia: data of a prospective study. J Am Soc Nephrol 14: 234\u2013239","journal-title":"J Am Soc Nephrol"},{"key":"958_CR49","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.2165\/00003495-200464240-00004","volume":"64","author":"Slifkin","year":"2004","unstructured":"Slifkin M, Doron S, Snydman DR (2004) Viral prophylaxis in organ transplant patients. Drugs 64: 2763\u20132792","journal-title":"Drugs"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-005-0958-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-005-0958-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-005-0958-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T03:18:46Z","timestamp":1626751126000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-005-0958-6"}},"subtitle":["Standard oder ma\u00dfgeschneidert?"],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["958"],"URL":"https:\/\/doi.org\/10.1007\/s00120-005-0958-6","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}